Serial plasma brain natriuretic peptide testing in clinical management of pulmonary arterial hypertension

Acta Cardiologica Sinica

Volumn 25, Issue 3, 2009, Pages 147-153

  Ho, Wan Jing ^a   Hsu, Tsu Shiu ^a   Tsay, Pei Kwei ^c   Hsu, Lung An ^a   Wang, Chun Li ^a   Chang, Chi Jen ^a   Yu, Kuang Hui ^b   Chen, Ji Yih ^b   Kuo, Chi Tai ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Brain natriuretic peptide; Combination therapy; Endothelin receptor antagonist; Pulmonary arterial hypertension

Indexed keywords

BOSENTAN; BRAIN NATRIURETIC PEPTIDE; ILOPROST; NITRIC OXIDE; SILDENAFIL;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FUNCTION; HUMAN; IDIOPATHIC DISEASE; LUNG ARTERY PRESSURE; MALE; MORTALITY; PATIENT COMPLIANCE; PERICARDIAL EFFUSION; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SYSTEMIC LUPUS ERYTHEMATOSUS; WORLD HEALTH ORGANIZATION;

EID: 70449576001     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Eng J Med 2004;351:1425-1436
2. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S-12S.
3. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S-24S. (Pubitemid 38759713)
4. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence- based clinical practice guidelines. Chest 2007;131:1917-1928 (Pubitemid 46981654)
5. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858-863 (Pubitemid 41632043)
6. Isaac DL. Biomarkers in heart failure management. Curr Opin Cardiol 2008;23:127-133
7. Tang WHW, Francis GS, Morrow DA, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007;116:e99-109.
8. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-870 (Pubitemid 30671502)
9. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypetension. Chest 2005;128:2368-2374 (Pubitemid 41507581)
10. Reesink HJ, Tulevski II, Marcus JT, et al. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 2007;84:537-543
11. Simeoni S, Lippi G, Puccetti A, et al. N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int 2008;28:657-660
12. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31:202-208 (Pubitemid 28064743)
13. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease. Part I: anatomy, physiology, aging, and functional assessment of right ventricle. Circulation 2008;117:1436-1448
14. Abbas AE, Fortuin FD, Schiller NB, et al. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol 2003;41:1021-1027
15. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005;330:625-636 (Pubitemid 40444756)
16. Chuang CP, Lo HM, Wu CY, et al. N-terminal pro-brain natriuretic peptide as a prognostic predictor in critical care patients with acute cardiogenic pulmonary edema. Acta Cardiol Sin 2007;23:20-28
17. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Eng J Med 2002;347:161-167 (Pubitemid 34764819)
18. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:1214-1219
19. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-1130 (Pubitemid 30172933)
20. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49: 1733-1739 (Pubitemid 46589928)
21. Galiè N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:1380-1386 (Pubitemid 36439000)
22. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-3111 (Pubitemid 40847788)
23. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)